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Abstract
mRNA therapeutics have become the focus of molecular medicine research. Various mRNA applications have
reached major milestones at high speed in the immuno-oncology field. This can be attributed to the knowledge
that mRNA is one of nature’s core building blocks carrying important information and can be considered as a
powerful vector for delivery of therapeutic proteins to the patient.
For a long time, the major focus in the use of in vitro transcribed mRNA was on development of cancer vaccines,
using mRNA encoding tumor antigens to modify dendritic cells ex vivo. However, the versatility of mRNA and its
many advantages have paved the path beyond this application. In addition, due to smart design of both the
structural properties of the mRNA molecule as well as pharmaceutical formulations that improve its in vivo stability
and selective targeting, the therapeutic potential of mRNA can be considered as endless.
As a consequence, many novel immunotherapeutic strategies focus on the use of mRNA beyond its use as the
source of tumor antigens. This review aims to summarize the state-of-the-art on these applications and to provide a
rationale for their clinical application.
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Background
Cancer is an umbrella term for life-threatening diseases
that are characterized by an uncontrolled growth of
transformed, malignant cells that, when left untreated,
can disseminate throughout the body. Treating cancer is
challenging, as conventional therapies, such as surgery,
radiotherapy and chemotherapy, although improved, are
unable to prevent disease recurrence in a significant
number of patients [1].
A better understanding of the tumor and its environ-
ment, in particular the knowledge that various immune
cells, such as natural killer (NK) cells and CD8+ T cells,
can infiltrate tumors and can act in concert to kill tumor
cells, has fueled the development of novel cancer therapy
strategies that aspire activation of the immune system.
Examples thereof are cancer vaccination, adoptive cell
therapy, the use of cancer-specific monoclonal anti-
bodies (mAbs) as well as modulation of the immunosup-
pressive tumor microenvironment (TME) with blockade
of inhibitory immune checkpoint pathways being exten-
sively studied [2–6]. These strategies, either alone or
combined with conventional therapies, have changed
how cancer is being treated anno 2020.
The use of in vitro transcribed (IVT) mRNA for devel-
opment of cancer therapeutics has received growing
interest. This is attributed to the knowledge that mRNA
is a powerful vector for delivery of therapeutic proteins
to the patient, which can be further potentiated through
modifications to the mRNA molecule as well as its for-
mulation in smartly designed nanoparticles [7]. In this
© The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: karine.breckpot@vub.be; Sandra.vanlint@ugent.be
†Karine Breckpot and Sandra Van Lint share senior authorship
6Laboratory for Molecular and Cellular Therapy, Department of Biomedical
Sciences, Vrije Universiteit Brussel, Laarbeeklaan 103 Building E, 1090 Brussels,
Belgium
4Cancer Research Institute Ghent (CRIG), Ghent University, Ghent, Belgium
Full list of author information is available at the end of the article
Van Hoecke et al. Molecular Cancer           (2021) 20:48 
https://doi.org/10.1186/s12943-021-01329-3
regard, the use of IVT mRNA encoding tumor antigens
has been extensively studied for the development of
potent cancer vaccines. The different steps in the devel-
opment of these mRNA-based vaccines have been exten-
sively described elsewhere [8, 9]. mRNA has also been
studied as a means to (1) deliver cancer-specific and im-
mune checkpoint blocking mAbs, (2) modulate the
tumor site itself to promote tumor cell killing and/or
inhibit immunosuppression or (3) generate tumor-
specific T cells. These non-tumor antigen mRNA-based
immunotherapy approaches have proven successful in
preclinical studies, which have encouraged their evalu-
ation in a clinical setting.
In this review, we provide a concise, yet comprehen-
sive overview of the current state-of-the-art on the use
of mRNA as a vector for in situ delivery of therapeutic
proteins beyond tumor antigens. These include mAbs or
antibody fragments, cytokines and proteins with immune
activating potential. As an exception to the in situ deliv-
ery of mRNA encoding therapeutic proteins, we also
introduce the use of mRNA for the therapeutic engin-
eering of tumor-specific T cells in the context of adop-
tive cell therapy. Because the efficacy of mRNA-
delivered therapeutic proteins largely depends on the
level, persistence and location of expression, we start this
review with discussing the requirements of IVT mRNA
for these approaches and strategies to efficiently deliver
the mRNA to the desired cell type and/or organ.
From structure to pharmacology: engineering mRNA
molecules for in vivo applications
Structural properties of IVT mRNA
IVT mRNA is synthesized in cell-free circumstances
from a linearized DNA template using highly efficient
and promotor-specific bacteriophage-derived RNA poly-
merases (SP6, T7 or T3) [10]. Fully processed mRNA
consists of five in cis-acting structural elements. From 5′
to 3′ end these include: (1) a cap structure; (2) a 5′
untranslated region (UTR); (3) the coding sequence of
the desired therapeutic protein; (4) a 3′ UTR and (5) a
sequence of repeated adenine nucleotides forming a
poly(A) tail. Technological advancements in mRNA
engineering, including the emergence of multiple vari-
ants of these individual structural elements, and their
impact on mRNA stability and translation efficiency are
the subject of many reviews [11–15].
Over the last decades, a better understanding of
mRNA’s structural biology has led to the production
of mRNA constructs with increasingly improved sta-
bility and translation capacity. A critical determinant
here is the recognition of mRNA molecules by innate
immune sensors. Upon cell entry mRNA molecules
are detected by pattern recognition receptors (PRRs),
including endosomal Toll-like receptors (TLR3 [16]
and TLR7/8 [17]) and cytosolic nucleic acid sensors
(MDA-5 and RIG-1) [18], which results in cytokine
signaling and the induction of anti-viral immunity.
While the innate immune activity of mRNA can be of
critical importance for the potency of mRNA-based
cancer vaccines, immunostimulatory effects should be
minimized for the mRNA-based approaches discussed
in this review [19]. Indeed, the onset of programmed
anti-viral mechanisms can drastically lower the mRNA
half-life and translation efficiency, while it is also a
potential driver of adverse effects [20, 21].
A major breakthrough in this regard, was the discovery
that post-translational modifications to the mRNA
nucleotides in mammalian cells prevent the immune
recognition of mRNA [22]. As an outstanding example,
the incorporation of N1-methyl-pseudouridine (1mΨ) in
mRNA was found to alter the interaction between
mRNA and PRRs (in particular TLR3, TLR7 and RIG-I),
thereby down-modulating the innate immune stimula-
tion by mRNA [23–25]. Moreover, a study by Mauger
et al. [26, 27] evidenced that the replacement of uridine
with 1mΨ stabilizes secondary structures in mRNA mol-
ecules, where they identified that a flexible leader region
and a high degree of secondary structure throughout the
remainder of the molecule correlated with a prolonged
functional half-life of mRNA and higher protein expres-
sion. Supported by findings of several studies [28, 29],
the authors suggested that incorporation of modified
uridine not only helps mRNA to evade innate immunity
but might also affect the binding and dynamics of
mRNA molecules with ribosomes. In addition, double
stranded RNA (dsRNA) impurities formed during tran-
scription significantly contribute to the innate immune
activity of mRNA therapeutics [30]. Purification of IVT
mRNA by means of high-performance liquid chromatog-
raphy (HPLC), or alternative simplified methods using
cellulose columns or selective digestion of dsRNA frag-
ments using RNAse III have been proposed [30–32]. In
an elegant study, Nelson and colleagues recently demon-
strated that by combining 1mΨ-modified mRNA with
the removal of dsRNA impurities through process
optimization and/or purification, mRNA products can
be obtained with an almost completely immunologically
silent and most favorable expression level [24]. Figure 1
gives an overview of the structural properties and design
of mRNA therapeutics.
Thess and colleagues showed in 2015 that
sequence-optimized, HPLC-purified, unmodified
mRNA can also achieve sufficient protein expression
and avoid immunogenicity [33]. In their study, the
codons of the open reading frame (ORF) are adapted
in order to improve translation and half-life of the
mRNA. To this end, only the most GC-rich codons
were used for each amino acid. Moreover, various
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biological sources were screened to identify potent
enhancer and stabilizer elements. In this way an opti-
mized ORF sequence is accompanied with an optimal
combination of untranslated sequences. Remarkably,
unmodified sequence-engineered mRNA constructs
could be as competitive as modified mRNA molecules
in large primates [33]. This is in contrast with the
reports of Karikó showing that incorporation of modi-
fied nucleotides leads to superior non-immunogenic
mRNA with increased translation and stability [30, 34,
35]. A possible explanation for this discrepancy arises
from variations in RNA sequence optimization, the
stringency of mRNA purification to remove dsRNA
contaminants and the level of innate immune sensing
in the targeted cell types.
Delivery systems – the success of mRNA lipid nanoparticles
By formulating mRNA in nanoparticles, the mRNA can
be protected from harsh biological conditions, and cellu-
lar uptake and release of the mRNA from endosomes
can be maximized, while the use of additional targeting
moieties and/or tuning of particle characteristics can
potentially promote organ- and cell-specific targeting.
Today’s most clinically advanced mRNA therapeutics
make use of lipid-based nanoparticles (LNPs). These
LNPs are typically manufactured in a single-step proced-
ure using microfluidic mixing devices, which enables
straightforward (up) scaling and translation from bench
to GMP. In these devices, an acidic aqueous solution of
mRNA is rapidly mixed with an ethanol solution of
lipids. By diluting the ethanol phase, the lipids undergo a
Fig. 1 Design and in vivo administration of mRNA therapeutics. Left box: mRNA product design. mRNA consists of five in cis-acting structural
elements: (1) a cap structure; (2) a 5′ untranslated region (UTR); (3) the coding sequence of the desired therapeutic protein; (4) a 3′ UTR and (5) a
sequence of repeated adenine nucleotides forming a poly(A) tail. By using modified nucleotides and extensive purification processes, the innate
immune stimulation characteristic of mRNA can be down-modulated. Nowadays, lipid-based nanoparticles (LNPs) are often used for the delivery
of mRNA therapeutics by making use of microfluidic mixing devices. In such devices, an acidic aqueous solution of mRNA is rapidly mixed with
an ethanol solution of lipids. By using LNPs, the mRNA is protected from degradation and is delivered to the cytosol. Optionally, specific targeting
entities can be added to the surface of LNPs to direct the mRNA-LNP to specific tissues or cells. Right box: in vivo administration of the mRNA
therapeutic. The systemic delivery of mRNA complexed in LNPs mainly target the liver due to the binding of apolipoprotein E and subsequent
receptor-mediated uptake by hepatocytes. To circumvent predominant hepatic uptake and expression, the lipid composition of the LNP can be
adjusted or specific targeting Abs can be added to the LNPs. Furthermore, upon local delivery by intradermal, intramuscular or subcutaneous
administration of mRNA-LNPs, mainly expression at the site of injection has been observed. Abbreviations: UTR: untranslated region; LNP: lipid-
based nanoparticles; TME: tumor microenvironment
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condensation process and spontaneously form lipid vesi-
cles while entrapping the mRNA. Standard components
of such LNP delivery system are (1) a cationic lipid,
which complexes the negatively charged RNA and facili-
tates cytosolic delivery, in combination with other struc-
tural “helper” lipids such as (2) cholesterol, (3)
phospholipids and (4) a diffusible polyethylene glycol
(PEG)-conjugated lipid.
A critical step in the optimization of LNPs, initially
for the delivery of small interfering RNA (siRNA),
was the introduction of a new class of “ionizable” cat-
ionic lipids. Most prominent examples are LNPs com-
posed with D-Lin-MC3-DMA or the lipidoid C12–
200 [36–38]. The apparent pKa value of these
ionizable lipids (pKa < 7) makes these lipids positively
charged during the RNA complexation (at low pH),
but LNPs remain relatively neutral at physiological
pH. In comparison to formulations previously used
for gene delivery, ionizable LNPs were found to be
much more powerful to transfect liver cells, while
charge-related toxicities could be minimized. A study
by Akinc et al. [39] demonstrated that this could be
attributed to the absorption of apolipoprotein E and
enhanced receptor-mediated clearance by hepatocytes
via the low-density lipoprotein receptor. Follow-up
studies demonstrated that by optimally adjusting pa-
rameters such as the molar ratios of lipids, the lipid-
to-RNA ratio, and/or type of phospholipid in the par-
ticle, liver targeting could be further improved which
eventually revolutionized the field with the approval
of Patisiran as a first-of-its-kind siRNA therapeutic in
humans [40].
Over time, the use of ionizable LNPs became com-
monplace for the in vivo delivery of mRNA [12, 41].
Recently, advances were made in discovery of new lead
ionizable lipids with enhanced bio-degradability, new
combinations with alternative helper lipids, such as chol-
esterol analogues and polysarcosine, as an alternative
surface modification to PEG [42–45]. When adminis-
tered systemically, LNPs provide an excellent approach
for direct delivery of mRNA therapeutics to liver can-
cers, or to exploit the liver as a factory site for the sys-
temic secretion of mRNA-encoded proteins [46, 47].
Moreover, LNP formulations can be designed to also tar-
get organ (cancer) tissues beyond the liver, maybe even to
achieve cell-specific delivery. Early reports showed that
LNP design can be optimized for the targeting of inflam-
matory monocytes and antigen-presenting cells (APCs) in
spleen and bone marrow [48, 49]. Other studies have
focused on the use of antibody conjugates to promote
receptor-mediated uptake by specific target cells, and as a
means to re-target LNPs to the lungs [50–52]. Cheng
et al. [53] presented an alternative approach called Select-
ive Organ Targeting (SORT), where they showed that by
the inclusion of an additional cationic or anionic lipid (i.e.,
SORT molecule), activity profiles of mRNA LNPs could
be shifted from the liver to the lungs and spleen. Although
the authors could clearly demonstrate organ-specific
mRNA expression, it remains to be elucidated whether
this can be the result of different cellular uptake patterns
for each of the investigated mRNA LNPs. Finally, mRNA
LNPs are also applicable to other administration routes,
including the direct injection of mRNA therapeutics in
tumor lesions [54, 55]. Of note, mRNA vaccines using
LNP technologies for intramuscular administration are set
to become the first vaccines in the fight against COVID-
19 [56, 57]. Together, LNPs have strongly catalyzed the
clinical applicability of mRNA therapeutics and based on
their design flexibility, opened a wide range of new thera-
peutic opportunities.
The applications of mRNA therapeutics for cancer
immunotherapy beyond tumor antigen vaccination
mRNA for delivery of mAbs
Recombinant, full-sized mAbs and antibody fragments,
such as single chain variable fragments (scFv) and heavy
chain only VH domains (VHHs, nanobodies), that target
tumor antigens, tumor stromal factors, immune cells or
immune pathways, have been studied as therapeutics in
the field of immune-oncology (Fig. 2) [58, 59]. Moreover,
antibody fragments have been used as building blocks
for bispecific antibody formats and chimeric antigen
receptors (CARs), a component in adoptive cell therapy,
thereby making antibody fragments an invaluable asset
in the immuno-oncology arsenal.
Many challenges associated with the use of mAbs and
antibody fragments became apparent with the advance-
ment of this field, among which cost-efficient production
of these proteins and ensuring sufficiently high levels at
the site of action, two challenges for which it is con-
tended that IVT mRNA can provide a solution [60, 61].
mRNA is capable of encoding any protein. Therefore, it
is possible to encode full-size mAbs, antibody fragments
or any variants designed with these antibody fragments.
The delivery of this mRNA to cells and the subsequent
production of these proteins by the cells ensures proper
assembly and post-translational modification, which is
particularly critical for the function of full-size mAbs
[62]. The mRNA molecule and its mode of delivery can
be tweaked to ensure prolonged protein expression at
the site of interest, for instance the TME, implying that
mAb levels can be sustained locally and over a period of
time. This holds the promise of increased efficacy and
decreased toxicity. Research to evaluate mRNA as an
efficient vector for delivery of (bispecific) antibodies has
been performed in view of activating anti-tumor
immune responses. The choice for focusing on these
approaches is obvious, as jumpstarting the anti-tumor
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immune response could be sufficient to set off a cascade
of immune activities that cooperate to eradicate cancer
cells, providing long-lasting benefit.
We refer to excellent reviews covering (1) the
deprivation of cancer cells from nutrients and oxygen
through the use of mAbs that target vascular growth fac-
tors or stromal factors, ultimately resulting in cancer cell
death [63] as well as (2) the targeting of receptors on
cancer cells to block essential growth signals [64], to de-
liver cell death-inducing signals [65], or to simply act as
anchoring points for delivery of toxic payloads [66]. In
this section, we will focus on how mRNA encoding anti-
bodies and their derivatives has been exploited to fight
cancer and how the mRNA-encoded antigen-binding
moiety activates anti-tumor immunity making use of dif-
ferent strategies.
One strategy that relies on the activation of anti-
tumor immunity involves leveraging of effector func-
tions of the Fc region of cancer-specific mAbs to
initiate complement-dependent cytotoxicity (CDC),
antibody-dependent cellular phagocytosis (ADCP) or
antibody-dependent cellular cytotoxicity (ADCC) [67].
Rituximab is a clinically approved IgG1 mAb that
targets CD20 and induces CDC and to lesser extent
ADCC [68]. This mAb has been encoded in mRNA,
an approach that has shown benefit in a preclinical B
cell lymphoma model. More specifically, Thran et al.
[69] encoded the codon-optimized sequence of the
rituximab heavy and light chain on two separate plas-
mids for production of mRNA. The mRNA was pro-
duced with unmodified nucleotides, purified using
HPLC, admixed at equimolar ratios and formulated in
LNP for in situ delivery to hepatocytes. Mice bearing
CD20+ Raji cells were treated twice per week with
escalating doses of the rituximab mRNA-LNP, show-
ing dose-dependent tumor control. Notably, a signifi-
cant number of mice showed tumor rejection at the
50 μg rituximab mRNA-LNP dose, while mice treated
with 200 μg rituximab (control group) showed a worse
outcome.
Fig. 2 The structure and application of antibody (fragments) for cancer therapy. Left box: IgG antibodies (150 kDa) as found in humans consist of
a Fab and Fc fragment, which are linked through a hinge region. The Fc fragment consists of constant regions from the heavy chain (CH), while
the Fab fragment consists of constant and variable domains of the heavy and light chain (CH, VH and CL, VL respectively). Heavy chain only
antibodies (HcAbs, 75 kDa) as found in camelids lack light chains. Examples of antibody fragments are single chain variable fragments (scFvs, 30
kDa) and heavy chain only VH domains (VHHs, nanobodies, 15 kDa). Right box: Antibodies are exploited to induce Fc-mediated anti-tumor
immunity through activation of complement factors (CDC), macrophages (ADCP) or NK cells (ADCC). Antibodies and antibody fragments are also
used to activate T cells with cytolytic activity. Bispecific T cell engagers (BiTEs) form a bridge between cancer cells and T cells. Chimeric antigen
receptors (CARs) allow T cells to recognize and kill cancer cells independent of antigen presentation in human leukocyte antigens (HLAs).
Blockade of inhibitory immune checkpoints, such as that consisting of programmed death-1 (PD-1) and its ligand (PD-L1), releases the brake on T
cell activity. Antibodies and antibody drug conjugates are exploited to directly act on cancer cells, depriving them from survival signals or growth
factors, activating cell death pathways or delivering toxic payloads. Abbreviations: ADCC: antibody-dependent cellular cytotoxicity; ADCP:
antibody-dependent cell phagocytosis; BiTE: bispecific T cell engager; CAR: chimeric antigen receptor; CDC: complement-dependent cytotoxicity;
CH: constant domain of the heavy chain; CL: constant domain of the light chain; Fab: fragment, antigen binding; Fc: fragment crystallizable
region; HcAb: heavy chain only antibody; HLA: human leukocyte antigen; PD-1: programmed death-1; PD-L1: programmed death-ligand 1; VH:
variable domain of the heavy chain; VHH: variable domain of the heavy chain only antibody; VL: variable domain of the light chain
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Second, particular attention should be devoted
towards the use of bispecific antibodies that simultan-
eously bind cancer- and T cell-specific surface proteins,
thereby redirecting and activating T cells to kill cancer
cells [70]. To that end, a scFv from an antibody targeting
a cell surface molecule on T cells (often CD3ε) is linked
through a short flexible linker to a scFv from an anti-
body targeting an antigen on the surface of cancer cells.
These are commonly referred to as bispecific T cell
engagers or BiTEs [71]. The BiTEs that were so far
encoded in IVT mRNA targeted CD3 in combination
with claudin 6 (CLDN6) or epithelial cell adhesion mol-
ecule (EpCAM) [46]. The IVT mRNA used to encode
these BiTEs was improved in terms of stability and
translational efficacy through modifications to the UTRs,
cap and poly(A) tail. The transfection reagent TransIT®
was used to encapsulate the BiTE mRNA, and to medi-
ate its uptake and expression in the liver upon intraven-
ous injection. Using modified nucleotides during the
production of mRNA was required to obtain high BiTE
plasma levels. Notably, BiTE plasma levels were still de-
tectable at 72 h, at which time recombinant BiTE pro-
teins, the control, were no longer detectable in the
plasma. Picomolar concentrations of the mRNA-
encoded BiTEs was sufficient to mediate cell lysis in an
ex vivo cytotoxicity assay. In vivo, both CLDN6xCD3
and EpCAMxCD3 BiTEs encoded in mRNA were used
to treat ovarian carcinoma (OV-90) and human periph-
eral blood mononuclear cell transplanted NSG mice.
The treatment was performed over a period of 3 weeks
and consisted of 3 μg of BiTE mRNA per week. For
comparison, a cohort of mice was treated for 3 weeks
with three to four injections per week of 200 μg/kg of re-
combinant BiTE proteins. Tumor control was reached in
all mice.
Finally, antibodies that act on immune checkpoints,
pathways installed to stimulate or inhibit immune activa-
tion, have revolutionized standard-of-care for several
cancer indications. In this regard, mAbs blocking the in-
hibitory immune checkpoint consisting of cytotoxic T
lymphocyte-associated antigen-4 (CTLA-4), pro-
grammed death-1 (PD-1) and its ligand PD-L1, are con-
sidered game changers in the field of oncology [72, 73].
As a more recent development, nanobodies that bind
and block CTLA-4 or PD-L1 have shown potential in
view of immune activation at the priming as well as the
effector stage of T cells [74–77]. However, as these path-
ways are critical regulators of T cell activation, attention
should be paid towards careful regulation of amongst
others optimal doses and administration schedules to
avoid immune related auto-reactivity and toxicity [78].
To circumvent these safety issues, the use of mRNA en-
coding immune modulators can be considered as a
promising strategy. Although, Pruitt et al. described local
modulation of immune checkpoints at the TME, this
was achieved by ex vivo transfection of DCs with mRNA
encoding the H and L chains of anti-CTLA-4 and anti-
GITR mAbs [79]. Based on this technology, a clinical
study for patients with metastatic melanoma was initi-
ated (NCT01216436). Thus far, studies focusing on the
in vivo manipulation of immune modulators using
mRNA have not yet been reported, although preclinical
studies on this topic are ongoing.
All together, these studies are a first testimony of the
potential of mRNA-mediated delivery of antibodies and
antibody derivatives, and warrant further research into
this technology platform for systemic or local production
of these proteins in a transient fashion, yet achieving a
more interesting pharmacokinetic profile when com-
pared to delivery of recombinant proteins.
mRNA for induction of cell death in cancerous cells
mRNA therapeutics can also be used to force diseased
cells to synthesize a toxic intracellular protein, causing
cells to self-destruct (Fig. 3, panel 1). For this type of ap-
proach, it is of utmost importance to express the toxic
protein exclusively in the target cells. Unfortunately,
current nanoparticle-based mRNA delivery methods ex-
hibit a high propensity for expression in the liver upon
systemic administration. To circumvent this, Jain and
colleagues showed that the inclusion of microRNA tar-
get sites in therapeutic mRNAs encoding apoptotic pro-
teins, caspase or PUMA, can prevent their expression in
healthy hepatocytes while triggering apoptosis in hepato-
cellular carcinoma cells [87]. Such miRNA-mediated
elimination of liver toxicity could be very effective for
systemic administration of modified mRNAs.
Next to this approach, Van Hoecke and colleagues
evaluated intratumoral injection of hypo-inflammatory
mRNA encoding the key execution protein in the
necroptosis pathway, MLKL, immediately followed by
electroporation of the tumor [80]. Moreover, hypo-
inflammatory mRNA was manufactured for delivery of
tBID [88], the truncated Bcl2-like inducer of cell death,
which induces apoptosis. In vitro transfection of B16
(melanoma) and CT26 (colon carcinoma) tumor cells
with MLKL or tBID was achieved using Lipofectamine™
as a transfection agent, while in vivo delivery of the
mRNA was achieved through electroporation. Both tBID
and MLKL mRNA induced significant cell death in vitro
and delayed tumor growth in vivo. In these experiments,
mRNA encoding MLKL showed the best therapeutic
index. It was shown that intratumoral delivery of MLKL
mRNA stimulates anti-tumor immunity against neo-
epitopes, a process that was dependent on CD8α+ DCs,
which are proficient in antigen cross-presentation.
Moreover, it was shown that type I interferon (IFN) was
key in the immune activation [80].
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The use of mRNA to modulate tumor-associated dendritic
cells
Several DC subtypes have been identified in the TME of
different murine and human cancers. Commonly, these
are referred to as tumor-associated DCs (TADCs).
Although the function of TADCs is partly lineage-
specific, where specific subsets such as conventional
DC1 seem hardwired for efficient cross-presentation of
tumor antigens, a large body of evidence points to cor-
ruption of immunogenic DC functions by TME-related
factors. TADCs are rendered defective in their immune
activating capacity among others by hypoxia, accumula-
tion of adenosine and lactate, and a number of cyto-
kines, including vascular endothelial growth factor
(VEGF), interleukin-10 (IL-10), and prostaglandin E2
(PGE2) [89–93]. Nonetheless, it was shown that TADCs
can acquire tumor antigens and when lifted from the
TME can activate tumor antigen-specific T cell
responses [92].
Therefore, reprogramming TADCs (Fig. 3, panel 2), to
acquire a T cell-activating phenotype, has been studied
using an mRNA-based approach, in particular by intra-
tumoral injection of TriMix mRNA [94]. TriMix is an
mRNA-cocktail composed of three mRNA molecules
encoding CD40L, CD70 and a constitutive active form
of TLR4 (caTLR4) and could be considered as a new
standard for DC activation [81–84]. Local administration
of so-called “naked” mRNA results in its selective uptake
by and expression in cross-presenting CD8α+ DCs. As a
consequence, injection of TriMix mRNA enables repro-
gramming of CD8α+ TADCs, as shown by the acquisi-
tion of a mature phenotype and the ability to migrate to
Fig. 3 The in vivo application of mRNA to modulate the tumor microenvironment. (1) Use of mRNA for induction of cell death in diseased cells
e.g. mRNA encoding MLKL enforce cells to die in an immunogenic way [80] (2) Use of mRNA to modulate tumor-associated dendritic cells (TADC)
e.g. mRNA encoding for CD40L, CD70 and caTLR4 (TriMix) can be combined to stimulate immature TADC to mature TADC [81–84]. (3) Use of
mRNA to modulate suppressive cell types e.g. mRNA encoding IKKβ is used to genetic reprogram tumor-associated macrophages [85]. (4) The use
of mRNA to modulate the cytokine milieu e.g. mRNA encoding IFN-β fused to the ectodomain of the TGF-β receptor II (Fβ2) [86]. (5) Use of
mRNA for generation of cancer-specific T cells. mRNA can be used to genetic engineer T cells to express cancer-specific T cell receptors or
chimeric antigen receptor. Abbreviations: MLKL: Mixed lineage kinase domain like pseudokinase; CD40L: Cluster of differentiation 40 ligand; CD70
Cluster of differentiation 70; caTLR4: constitutive active toll like receptor 4; M2: macrophage type 2 phenotype; M1: macrophage type 1
phenotype; IKKβ: Inhibitor of nuclear factor kappa-β kinase; MDSC: Myeloid-derived suppressor cell; CAF: Cancer-associated fibroblast; Fβ2: IFN-β
fused to the ectodomain of the TGF-β receptor II; TCR: T cell receptor; CAR: chimeric antigen receptor
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lymph nodes and activate T cells. By injecting tumor-
bearing mice with TriMix mRNA, a delay in tumor
growth was obtained without the need to co-deliver
defined tumor antigens. This possibility to exploit the
tumor’s own antigenic repertoire by TriMix administra-
tion was shown in models of primary as well as dissemi-
nated tumors [94]. Currently a clinical trial to study the
safety and immunomodulatory effect upon intratumoral
delivery of TriMix mRNA in patients with early breast
cancer is ongoing (NCT03788083).
Similar to this study Haabeth et al. [95] used charge-
altering releasable transporters (CARTs) to deliver
mRNA encoding co-stimulatory molecules to TADCs in
a two-sided A20 model, representing disseminated can-
cer. Notably, CARTs enabled transfection of T cells and
tumor-associated macrophages (TAMs) as well. Delivery
of CD70 mRNA only marginally affected tumor growth
in both the treated and non-treated tumor. In contrast,
CART-mediated delivery of OX40L mRNA induced re-
gression in 100% of treated tumors, while a delay in
growth was observed in the non-treated tumors. Similar
results were obtained upon delivery of CARTs loaded
with mRNA that encoded the co-stimulatory molecules
CD80 and CD86. It was shown that transfected TADCs
migrated to lymph nodes, suggesting a similar mode of
action as described by Van Lint et al [94]. Nonetheless,
it cannot be excluded that T cells and TAMs contribute
to this therapeutic effect. Transfected T cells were also
detected in lymph nodes, at least suggesting that these T
cells could exert effector functions at distal sites.
The use of mRNA to modulate suppressive cell types in the
tumor microenvironment
The tumor forms a dense network of both malignant
and non-malignant cells. Several immune cells present
in the TME are key regulators in the immunosuppres-
sive milieu and as such further contribute to the tumor-
promoting angiogenesis and formation of metastases
[96, 97]. Of these, cancer-associated fibroblasts (CAFs)
and TAMs can be considered as the most abundant
non-neoplastic cells found in the TME (Fig. 3, panel 3).
TAMs show the remarkable potential to respond to
environmental stimuli and many studies have shown
that modulation of TAMs can elicit anti-tumor T cell re-
sponses [98–101]. Genetic reprogramming of TAMs
using IVT mRNA has recently been described [102].
Intratumoral delivery of mRNA encoding costimulatory
and immune modulating factors by means of the CART-
nanoparticle technology, not only induced local modula-
tion of TADC as described in the previous paragraph
but additionally showed to be able to transfect TAMs as
well [95]. In line with this, Seif et al. described the pref-
erential transfection of type 2 TAMs upon recombinant
yeast delivery of biosynthesized mRNA. As such,
selective delivery of mRNA encoding the pro-
inflammatory regulators Myd88 and TNF to pro-
tumorigenic type 2 TAMs resulted in upregulation of
pro-inflammatory and cytotoxic cytokines and suggested
re-education towards TAMs with a pro-immunogenic
profile [103]. On top, Interferon Regulatory Factor 5
(IRF5) and IKKβ, a kinase that induces phosphorylation
and activation of IRF5 were shown as ideal master regu-
lators of TAM polarization to finally imprint TAMs with
a potent pro-inflammatory phenotype [85, 104]. Delivery
of a targeted nanocarrier formulated with IVT mRNA
encoding IRF5 and IKKβ, induced reversion of the sup-
pressive state of TAMs from a tumor-supporting pheno-
type towards a phenotype that induced anti-tumor
immunity and promoted tumor suppression [102].
Showing safety and efficacy in various preclinical mouse
tumor models (including ovarian cancer, melanoma and
glioblastoma), intraperitoneal administration of this
technology to treat ovarian cancer patients as a first clin-
ical translation of this therapy is envisaged (Fed Hutch-
inson Cancer Research Center).
In several cancers, intrinsic resistance to immunother-
apy is upheld by a connective tissue “shield” consisting
of dense extracellular matrix which is maintained by
CAFs. In addition, CAFs secrete a myriad of immuno-
suppressive factors. Selective targeting of CAFs, or more
specifically the CAF-specific fibroblast activating protein
(FAP), is capable of precipitating tumoral collapse in
preclinical tumor models [105, 106]. Although this has
spurred interest in the development of CAF-targeted
vaccine or CAR T-cell approaches, the potential of an
mRNA-based approach in this setting warrants research
efforts as well [107]. The feasibility of such an approach
is highlighted by several studies that used LNPs for de-
livery of plasmid DNA to CAFs, showing that delivery of
cell death inducing genes [108] or immunotherapeutic
agents [109, 110] is a valid approach.
The use of mRNA to modulate the cytokine milieu in the
tumor microenvironment
The cytokine milieu in tumors is determined by produc-
tion of various cytokines by immune and stromal cells
(e.g., fibroblasts, endothelial cells) [111]. It is the balance
of pro- and anti-inflammatory cytokines, their relative
concentration in combination with the cell composition
in the TME, hence type of cells that can be affected by
these cytokines, that determine the net effect of the
cytokine milieu [112]. This net effect can be categorized
as promoting versus countering tumor development and
dissemination. To date, several studies have exploited
mRNA as a vehicle to modulate the cytokine milieu
(Fig. 3, panel 4) [54, 55, 86, 113].
Intratumoral delivery of mRNA encoding a fusokine
called Fβ2, which consisted of IFN-β fused to the
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ectodomain of the TGF-β receptor II [86], was evaluated
to mimic the observations that were made earlier using
a combination of IFN-β and a TGF-β signaling antagon-
ist [114]. The idea behind this approach is dual: IFN-β
can increase immune reactivity, while the ectodomain of
the TGF-β receptor II can reduce TGF-β mediated
immunosuppression. The mRNA-encoded fusokine
reduced the immunosuppressive capacity of MDSCs,
while it enhanced the T cell stimulatory activity of DCs.
Tumor cell proliferation was affected by Fβ2 as well, al-
though it was observed that surviving tumor cells
expressed high levels of PD-L1. In situ delivery of Fβ2 re-
sulted in a delay in tumor growth, which could be fur-
ther enhanced through additional blockade of PD-1/PD-
L1 interactions [86]. The Fβ2 mRNA was delivered in its
“naked” form to tumors and as such depended on
TADCs to serve as a kind of factories to produce and se-
crete the fusokine.
Several pharmaceutical formulations have been studied
for delivery of mRNA that encodes for cytokines to cells
residing in the TME [54, 55, 95]. Cytokines that have
been studied in this context are IL-12, IL-23, IL-36γ and
IFN-γ. Most of these cytokines have a narrow thera-
peutic window with a poor safety profile when adminis-
tered systemically [115, 116]. Their local delivery using
mRNA formulated in LNPs represents a safe approach
to leverage these cytokines anti-tumor effects. To initiate
responses to foreign pathogens, IL-36γ is a classic alarm
signal, whereas IL-23 centrally coordinates immune
responses to danger signals. The intratumoral delivery of
mRNA encoding these two cytokines induced a robust
anti-cancer response in different tumor models. On top,
the addition of mRNA encoding OX40 ligand (OX40L),
a T cell costimulatory cytokine, further increased the
response rates. Mechanistically, this treatment is
dependent on Batf3-dependent cross-presenting CD8α+
DCs and cytotoxic CD8+ T cells. The combination of
the IL-23/IL-36γ/OX40L triplet mRNA mixture with
checkpoint blockade was efficient in models otherwise
resistant to systemic immune checkpoint inhibition [54].
Similarly, the use of mRNA encoding IFN-γ or IL-12 ei-
ther alone or in combination with OX40L mRNA has
been tested in a model of disseminated cancer [95]. The
mRNA was delivered using CARTs to one tumor, as
such modifying and immediately acting on multiple cells
in the TME. This study showed that delivery of IFN-γ
mRNA delayed overall tumor growth, however, to a
lesser extent as delivery of IL-12 mRNA. Co-delivery of
OX40L mRNA enhanced the effect of both cytokines,
resulting in a further delay of tumor growth in case IFN-
γ and OX40L mRNA was delivered and even cure of
several mice when IL-12 and OX40L mRNA was deliv-
ered [95]. This outcome is not unexpected as IL-12 is an
important cytokine, known to guide the differentiation
of T helper 1 (Th1) cells as well as enhancing the cyto-
toxic activity of NK cells, NKT cells and CTLs [117].
Hewitt et al. showed that a single intratumoral injection
of LNP-formulated IL-12 mRNA induced strong CTL-
dependent tumor regression, systemic effects on distant
tumor sites and long-term immunity. The induced
effects were accompanied with transformation of the
Th1 TME [55]. These preclinical data are at the basis of
a phase I clinical trial in which patients with solid
tumors receive IL-12 mRNA intratumorally in combin-
ation with the PD-L1 blocking antibody darvulumab
(NCT03946800). Also, Malkova et al. described local de-
livery of mRNA encoding single chain IL-12, albeit in
combination with IFN-α, granulocyte macrophage-
colony stimulating factor (GM-CSF) and interleukin-15
(IL-15). This mRNA-based cytokine cocktail was deliv-
ered either alone or in combination with anti-PD-1
treatment against various murine tumor types. Prelimin-
ary results showed significant anti-tumor responses
when the mRNA-based cytokine mix was delivered
alone, which could be further improved by combination
with anti-PD-1 treatment [113]. A first-in-human dose
escalation and expansion study was initiated in patients
with advanced solid tumors (NCT03871348).
mRNA for generation of cancer-specific T cells
Adoptive T cell therapy is a catch-all term that covers
therapeutic approaches in which enriched or engineered
autologous cancer-specific T cells are administered. Pio-
neering work was performed in the ‘80s by Steven A.
Rosenbergh, who first described cancer regression after
the infusion of isolated, autologous tumor-infiltrating
lymphocytes (TILs) in combination with high doses IL-2
in patients with metastatic melanoma [112]. Unfortu-
nately, translation of this concept to other tumor types
was found difficult, requiring new ways to generate
cancer-reactive lymphocytes. This prompted genetic
engineering of T cells to express cancer-specific T cell
receptors (TCRs) or CARs (Fig. 3, panel 5) [4].
Adoptive T cell transfer classically entails ex vivo
modification of isolated autologous cells for which a
plethora of techniques and compounds for T cell engin-
eering have been evaluated, including mRNA. The most
prominent modification to T cells is the induction of
CAR or TCR expression, which is mainly achieved by
the use of retro- or lentiviral transduction, which unfor-
tunately entails a risk of insertional mutagenesis. In this
light, electroporation of CAS9 mRNA into human T
cells was used as an alternative for randomly integrating
viral vectors, as it allowed directed integration of a
CD19-specific CAR to the T cell receptor α constant
(TRAC) locus. This resulted in uniform CAR expression
as well as enhanced T cell potency [118]. Also, mRNA
encoding CARs or TCRs has shown merit: inducing
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temporary expression of CARs or TCRs could avoid the
occurrence of the cytokine release syndrome, an adverse
event related to permanent T cell activity [119–122].
Although reports indeed describe clear therapeutic bene-
fits of mRNA-CAR T cell therapies, the other side of the
coin is the induction of human anti-mouse antibodies
(HAMA) due to the repeated dosing of mRNA-modified
CAR T cells, which were reported to result in IgE-
mediated anaphylactic shock [123]. Furthermore, mRNA
also showed potential to improve the functionality of
therapeutic T cells, e.g., by transfection with mRNA
encoding (membrane-bound) cytokines [124, 125]. The
use of mRNA for modification of T cells and its preclin-
ical efficacy as well as evaluation in a clinical setting is
extensively reviewed elsewhere [126].
It is evident that in these applications, the main goal is
to achieve high, but temporary, gene expression. This
provides a clear rationale for the use of minimally
immunogenic mRNA with a high translation efficiency.
Indeed, murine T cells electroporated with CAR-
encoding mRNA, were shown to exhibit a drastically re-
duced up-regulation of checkpoint molecules (PD-1 and
LAG-3) when chemically modified 1mΨ mRNA and/or
mRNA that was additionally purified to remove dsRNA
was used, as compared to their unmodified and unpuri-
fied counterparts. This equipped the immunosilent
mRNA-transfected T cells with an improved killing effi-
cacy that lasted even after the CAR expression by the
cells was already lost [32].
Despite successes obtained with T cell therapies in
hematological malignancies and the recent FDA
approval of the third CAR T cell therapeutic [127], their
complex manufacturing and difficulties in upscaling
remain largely unaddressed. Unfortunately, directly
modifying T cells in vivo, as compared to APCs, is an ar-
duous task as T cells are notoriously hard to transfect. A
few promising reports were published on the in vivo
engineering of CAR T cells via administration of lenti-
viral vectors [128, 129] or DNA-nanoparticles [130]. For
mRNA, merely a single study reports on the use of bin-
ary mixtures of CARTs for transfection of T cells, albeit
with limited efficiency and selectivity: only 1.5% of
splenic CD8+ T cells were transfected after intravenous
administration of the mRNA-CARTs, while at least 10-
fold higher transfection rates were observed in macro-
phages, DCs and B cells [131].
Bringing mRNA-based immunomodulation to oncological
practice: current challenges and future perspectives
For every new candidate anti-cancer therapy, a success-
ful journey from promising experimental concept to suc-
cessful implementation in patients entails major risks
which are situated at 3 levels: manufacturing, safety and
demonstration of clinical efficacy. In the case of mRNA,
the capacity to manufacture a GMP-compliant
nanoparticle-based product at (very) large scale has re-
cently been demonstrated in the context of Covid-19
vaccine development. The experience that is being ac-
quired with respect to industrial-scale production, stor-
age and distribution will undoubtably benefit the field of
mRNA-based cancer therapeutics as well.
As for safety, awareness of the regulatory framework
where mRNA-based therapeutics are situated today is
important. Despite the limited persistence of mRNA
in vivo and the virtually non-existent risk for genomic
integration or insertional mutagenesis, both EMA and
FDA consider mRNA-based medicines as bona fide gene
therapy. This perception may change however consider-
ing the way regulatory authorities are fast-tracking ap-
proval of mRNA-based vaccines against SARS-Cov2 for
deployment at massive scale. Still, transition to first-in-
human studies require prior rigorous documentation of
pharmacokinetics, pharmacodynamics, biodistribution
and shedding of the product. Because mRNA-based im-
munomodulators are primarily targeted at disseminated
cancers, these agents will most often be administered via
systemic route. Specifically targeting the injected dose to
the microenvironment of tumoral sites rather than nor-
mal tissue in a given organ or in multiple affected organs
is a considerable clinical challenge. Preclinical strategies
allowing to reduce hepatic accumulation (and resulting
toxicity), or even favor distribution to spleen or lung are
still too crude with that respect [53, 87]. More cancer-
selective targeting approaches may exploit the extreme
metabolic environment inside aggressively developing
tumor beds, i.e. the profound hypoxia and lactate-
induced acidic pH. The physicochemical properties of
LNPs could be fine-tuned to favor selective trapping and
accumulation in the acidic intratumoral environment.
Alternatively, incorporation of hypoxia-activated pro-
drugs in the nanoparticle formulation may yield novel
ways to target the mRNA cargo to fast growing tumors
where oxygen levels are extremely low. A different strat-
egy may use nanoparticle carriers functionalized with
molecules allowing targeting to tumor-specific vascular
markers [132]. For instance, RGD-peptides or anti-
CD105 antibodies can endow nanomaterials with specifi-
city to resp. αvβ3 integrin or endoglin, both of which are
highly enriched on the intratumoral endothelial surface.
As the lethality of many cancers results from the de-
velopment of cerebral metastases which are typically re-
fractory to many existing therapies, designing mRNA
carrier formulations able to cross the blood-brain barrier
could be a real game-changer. A successful proof-of-
concept of this approach was recently described, making
use of LNPs doped with neuro-transmitter precursor
molecules, and containing an active cargo -in casu an
antisense RNA molecule [133].
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Whichever formulation used for an mRNA-based can-
cer therapeutic, clinical development will in most cases
involve a combination regimen, typically on top of exist-
ing standard-of-care cancer therapy, be it radiotherapy,
chemotherapy, oncogene-targeted therapy, immune
checkpoint blockade or adoptive T cell therapy. Com-
bination trials will dominate the clinical trial landscape
in immuno-oncology for years to come, with the large
majority evaluating an investigational drug on top of an
immune checkpoint inhibitor backbone (reviewed in
Tang et al. [134]). The spectacular and seemingly
anarchic proliferation of immuno-oncology combination
trials calls for a more rationalized approach, where the
combination partner will have to be selected based on a
profiling of the dominant immunosuppressive mechan-
ism for a given tumor or patient. Early steps towards this
“precision immuno-oncology” paradigm are already
being taken, especially in tumor entities with a high
occurrence of primary or acquired resistance to
standard-of-care immunotherapeutics [135, 136]. With
its inherent versatility, mRNA-based immunomodulation
seems extremely well suited to be integrated in this
approach.
Conclusion
IVT mRNA has tremendous potential to become the
basis of a disruptive technology in oncology. This is
due to the promise mRNA therapeutics hold as
effective, safe and affordable strategy. Moreover, the
growing knowledge of formulations that allow protec-
tion of the mRNA as well as selective delivery of the
mRNA to an organ or cell of interest has further
boomed the field of mRNA therapeutics. Although
tremendous progress in research and the promising
potential, the latter still poses a challenge that needs
more in-depth investigation on how LNP formulations
can specifically deliver mRNA to the desired target.
While some cell-specific LNPs have been developed,
e.g. clinically approved “Onpattro” formulation, it is
still a large unknown which specific immune cell sub-
sets are targeted by playing with LNP compositions.
The first field of entry for mRNA therapeutics was the
cancer vaccination field. The development and applica-
tion of mRNA therapeutics for treatment of cancer has
boomed in the past years. In general, mRNA-based
cancer vaccination can be divided in two approaches.
The most obvious one is the immunization of patients
with mRNA encoding tumor antigens. As mRNA thera-
peutics have a flexible production process, this patient
immunization can be done on a personalized level. The
second approach explores the use of mRNA to reshape
the TME by delivering mRNA encoding stimulatory
molecules, blockade of inhibitory molecules and immune
checkpoint blockade to restore immunological fitness at
the tumor site. The immunosuppressive TME is a major
obstacle in cancer immunotherapy. Thanks to a growing
insight into the suppressive mechanism of the TME,
possible ways to block tumor escape are currently under
investigation, including the delivery of cytokines, decoy
receptors or other secreted immune modulatory
proteins.
Today, much effort is put into the use of immune
checkpoint inhibitors. However, immune checkpoint
blockade fixes only one late step in the chain leading to
T cell induced tumor destruction. To achieve complete
and safe eradication of tumor cells, cancer immunother-
apy should focus on combined therapies. This is key to
outsmart tumor escape mechanisms and (re-)induce an
equilibrium state of cancer immunoediting. As described
in this review, many strategies using mRNA as a vector
for in situ delivery of therapeutic proteins to restore
immunological fitness at the tumor site.
Altogether, the use of mRNA-based strategies has
evolved the therapeutic landscape at high speed. In this
fast-evolving world of cancer therapy, future combina-
tions of mRNA-based immunotherapies should be mat-
ter of investigation.
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